Research at St Thomas’s Hospital Exploring Causative Factors of Atopic Eczema and Food Allergy in Infants | Technology Networks Research at St Thomas’s Hospital Exploring Causative Factors of Atopic Eczema and Food Allergy in Infants
Research at St Thomas’s Hospital Exploring Causative Factors of Atopic Eczema and Food Allergy in Infants
AE development depends on host genetic and environmental factors, the focus of this study is to decipher their interplay and contribution to disease development.
St Thomas’s hospital researchers are integrating a detailed assessment of the bacterial species in infant skin and gut, and have prospectively collected environmental exposure data, specialist diagnosed AE, filaggrin mutation information and skin barrier assessment as well as gold standard double-blind placebo controlled food challenges on the same cohort of children. This will give an unprecedented insight into AE and its drivers.
Isohelix are providing technical support to this study by carrying out DNA isolations on infant samples which are then DNA sequenced. Next Generation Sequencing technology is being employed to characterize both skin and gut bacteria communities at 3, 5 and 12 months of age with regard to species diversity. Results will be nested within the EAT (Enquiring About Tolerance) Study (link below), a trial investigating the development of early onset AE and food allergy.
Research at St Thomas’s Hospital Exploring Causative Factors of Atopic Eczema and Food Allergy in Infants | Technology Networks Research at St Thomas’s Hospital Exploring Causative Factors of Atopic Eczema and Food Allergy in Infants
Research at St Thomas’s Hospital Exploring Causative Factors of Atopic Eczema and Food Allergy in Infants
AE development depends on host genetic and environmental factors, the focus of this study is to decipher their interplay and contribution to disease development.
St Thomas’s hospital researchers are integrating a detailed assessment of the bacterial species in infant skin and gut, and have prospectively collected environmental exposure data, specialist diagnos
ed AE, filaggrin mutation information and skin barrier assessment as well as gold standard double-blind placebo controlled food challenges on the same cohort of children. This will give an unprecedented insight into AE and its drivers.
Isohelix are providing technical support to this study by carrying out DNA isolations on infant samples which are then DNA sequenced. Next Generation Sequencing technology is being employed to characterize both skin and gut bacteria communities at 3, 5 and 12 months of age with regard to species diversity. Results will be nested within the EAT (Enquiring About Tolerance) Study (link below), a trial investigating the development of early onset AE and food allergy.